SecBot SecBot
144 ·Filed May 13, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago SEC0001959173-26-003553
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor subsequent Form 4 filings to confirm execution. This small insider sale is unlikely to move the stock. No change to investment thesis given strong analyst consensus.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.60
T+0 close · May 13, 2026 · via day close
Latest settled
−2.29%
T+60 · $9.38
Vs SPY
−6.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $9.60entry
  2. T+1 · 6mo ago −0.31%α −1.09% · $9.57
  3. T+5 · 6mo ago −8.96%α −8.82% · $8.74
  4. T+20 · 5mo ago −11.46%α −10.85% · $8.50
  5. T+60 · 3mo ago −2.29%α −6.73% · $9.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Officer Alane P. Barnes filed a Form 144 indicating intent to sell 62,500 shares of BioCryst Pharmaceuticals (BCRX), valued at approximately $596,250. The shares are from an option grant dated 2017. Given the relatively small size relative to market cap ($2.2B) and no apparent negative catalyst, the filing is routine.

Key Facts

  • Reporting person: Alane P. Barnes (Officer)
  • Proposed sale: 62,500 shares of common stock
  • Estimated value: $596,250 (based on filing date price)
  • Shares acquired via option granted on 12/20/2017
  • Sale intended for cash; filed on 05/13/2026

Financial Impact

Approximately $596,250, representing ~0.027% of market cap

dilutioninsider holdings

Risk Factors

  • Potential for larger unannounced insider sales if this is part of a planned selling program
  • No specific risk from this filing alone

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-003553
Document: 0001959173-26-003553-index.html0001959173-26-003553
Document: 0001959173-26-003553.txt0001959173-26-003553

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026